JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Search

Stevanato Group SpA

Chiusa

SettoreSettore sanitario

15.69 1.42

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

15

Massimo

15.78

Metriche Chiave

By Trading Economics

Entrata

10M

49M

Vendite

23M

303M

P/E

Media del settore

28.8

90.422

EPS

0.162

Rendimento da dividendi

0.31

Margine di Profitto

16.205

Dipendenti

5,521

EBITDA

10M

73M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+73.3% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.31%

2.13%

Utili prossimi

5 mar 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-2B

4.7B

Apertura precedente

14.27

Chiusura precedente

15.69

Notizie sul Sentiment di mercato

By Acuity

50%

50%

147 / 352 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Stevanato Group SpA Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 feb 2026, 23:52 UTC

Acquisizioni, Fusioni, Takeovers

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2 feb 2026, 23:52 UTC

Acquisizioni, Fusioni, Takeovers

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2 feb 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2 feb 2026, 23:38 UTC

Discorsi di Mercato

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2 feb 2026, 23:28 UTC

Discorsi di Mercato

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2 feb 2026, 23:23 UTC

Utili

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2 feb 2026, 22:57 UTC

Utili

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 22:22 UTC

Acquisizioni, Fusioni, Takeovers

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2 feb 2026, 22:08 UTC

Discorsi di Mercato

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2 feb 2026, 21:51 UTC

Utili

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

2 feb 2026, 21:49 UTC

Utili

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2 feb 2026, 21:39 UTC

Utili

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:36 UTC

Utili

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2 feb 2026, 21:34 UTC

Utili

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:28 UTC

Acquisizioni, Fusioni, Takeovers

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2 feb 2026, 21:23 UTC

Utili

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2 feb 2026, 21:19 UTC

Utili

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2 feb 2026, 21:17 UTC

Utili

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2 feb 2026, 21:17 UTC

Utili

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:10 UTC

Utili

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:08 UTC

Utili

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2 feb 2026, 21:07 UTC

Utili

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2 feb 2026, 21:05 UTC

Utili

Palantir Technologies 4Q Net $608.7M >PLTR

2 feb 2026, 21:05 UTC

Utili

Palantir Technologies 4Q Rev $1.41B >PLTR

2 feb 2026, 21:05 UTC

Utili

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2 feb 2026, 21:05 UTC

Utili

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2 feb 2026, 21:05 UTC

Utili

Palantir Technologies 4Q Adj EPS 25c >PLTR

2 feb 2026, 21:05 UTC

Utili

Palantir Technologies 4Q EPS 24c >PLTR

2 feb 2026, 20:40 UTC

Discorsi di Mercato

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Confronto tra pari

Modifica del prezzo

Stevanato Group SpA Previsione

Obiettivo di Prezzo

By TipRanks

73.3% in crescita

Previsioni per 12 mesi

Media 27 USD  73.3%

Alto 30 USD

Basso 24 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Stevanato Group SpA - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

3 ratings

2

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

21.56 / 22.61Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

147 / 352 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Stevanato Group SpA

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
help-icon Live chat